EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preliminary Data of the First Year of Newborn Screening for Metachromatic Leukodystrophy (MLD) in Lombardy

Alessandra Vasco iD, Andrea Meta, Clarissa Berardo iD, Davide Camerlengo, Francesca Fumagalli iD, Davide Tonduti, Iris Fiamingo, Cristina Montrasio iD, Diana Postorivo iD, Manuela Rizzetto, Sabrina Fede iD, Mld-Nbs Study Group und 8 weitere

International Journal of Neonatal Screening · 30.06.2026 · 12 (3) · 49

DOI: 10.3390/ijns12030049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 30.06.2026. Verfasst von Alessandra Vasco und 19 weiteren Autor:innen. Beteiligte Einrichtung: Center of Newborn Screening, Functional Genomics and Rare Diseases, Department of Pediatrics, Buzzi Children's Hospital, 20154 Milan, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Telethon Foundation, Buzzi Foundation, Fondazione Telethon.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metachromatic leukodystrophy (MLD) is a rare, autosomal recessive lysosomal storage disorder caused by a deficiency of the enzyme arylsulfatase A (ARSA, MIM #250100), which leads to progressive demyelination in the central and peripheral nervous systems, resulting in severe neurodegeneration and premature death. With the recent approval of the first ex vivo gene therapy for MLD, newborn screening (NBS) programs have begun to implement pilot studies for early detection, as identifying affected individuals during the pre-symptomatic therapeutic window is crucial. We present the analytical workflow and the NBS algorithm developed during the first year of MLD screening in Lombardy. The screening strategy comprised a first-tier test (1TT) using mass spectrometry to quantify sulfatide concentrations, a second-tier test (2TT) measuring ARSA enzymatic activity, and a third-tier test (3TT) based on whole-exome sequencing. A total of 16,130 newborns were screened for MLD. Of these, 6.41% required retesting (1TT), 1.53% underwent duplicate 2TT, and 0.36% proceeded to 3TT. No neonates were recalled, and no cases of MLD were identified through the screening program. The first-year implementation of MLD NBS in Lombardy demonstrates that a mass spectrometry-based sulfatide assay combined with a multi-tiered screening algorithm is feasible and reliable. Incorporating genetic analysis alongside expanded validation of additional sulfatide species may enhance specificity, reduce false positives, and facilitate timely identification of infants affected by MLD.

Schlagwörter

Stichwörter der Autor:innen

lysosomal storage disordermetachromatic leukodystrophy (MLD)newborn screeningsulfatidestandem mass spectrometry

Autor:innen und Institutionen

  • Center of Newborn Screening, Functional Genomics and Rare Diseases, Department of Pediatrics, Buzzi Children's Hospital, 20154 Milan, Italy.
  • Pediatric Research Center "Romeo ed Enrica Invernizzi", Department of Biomedical and Clinical Sciences, University of Milan, 20157 Milan, Italy.
  • San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), 20132 Milan, Italy.
  • Pediatric Immuno-Hematology Unit, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
  • Unit of Neurology, IRCCS Ospedale San Raffaele Milan, 20132 Milan, Italy.
  • Unit of Pediatric Neurology, C.O.A.L.A (Center for Diagnosis and Treatment of Leukodystrophies), V. Buzzi Children's Hospital, 20154 Milan, Italy.

ORCID-Profile: Alessandra Vasco, Clarissa Berardo, Francesca Fumagalli, Cristina Montrasio, Diana Postorivo, Sabrina Fede, Gianvincenzo Zuccotti, Stephana Carelli, Cristina Cereda

Förderung

  • Telethon Foundation
  • Buzzi Foundation
  • Fondazione Telethon

Zitieren

APA

Vasco, A., Meta, A., Berardo, C., Camerlengo, D., Fumagalli, F., Tonduti, D., Fiamingo, I., Montrasio, C., Postorivo, D., Rizzetto, M., Fede, S., Mld-Nbs Study Group, Bozic, R., Ferron, F., Calbi, V., Zuccotti, G., Aiuti, A., la Marca, G., Carelli, S., & Cereda, C. (2026). Preliminary Data of the First Year of Newborn Screening for Metachromatic Leukodystrophy (MLD) in Lombardy. International Journal of Neonatal Screening, 12(3), 49. https://doi.org/10.3390/ijns12030049

Vancouver

Vasco A, Meta A, Berardo C, Camerlengo D, Fumagalli F, Tonduti D, et al. Preliminary Data of the First Year of Newborn Screening for Metachromatic Leukodystrophy (MLD) in Lombardy. International Journal of Neonatal Screening. 2026;12(3):49. doi:10.3390/ijns12030049

BibTeX
@article{Vasco2026,
  author = {Vasco, Alessandra and Meta, Andrea and Berardo, Clarissa and Camerlengo, Davide and Fumagalli, Francesca and Tonduti, Davide and Fiamingo, Iris and Montrasio, Cristina and Postorivo, Diana and Rizzetto, Manuela and Fede, Sabrina and Mld-Nbs Study Group and Bozic, Roberto and Ferron, Francisco and Calbi, Valeria and Zuccotti, Gianvincenzo and Aiuti, Alessandro and la Marca, Giancarlo and Carelli, Stephana and Cereda, Cristina},
  title = {Preliminary Data of the First Year of Newborn Screening for Metachromatic Leukodystrophy (MLD) in Lombardy},
  journal = {International Journal of Neonatal Screening},
  year = {2026},
  volume = {12},
  number = {3},
  pages = {49},
  doi = {10.3390/ijns12030049}
}
Kostenlos starten →